Brief: LAVA Therapeutics NV Receives FDA Orphan Drug Designation For LAVA-051

LAVA Therapeutics NV

15/10/2021 14:43

Oct 15 (Reuters) - LAVA Therapeutics NV  LVTX.O :
    * LAVA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR
LAVA-051 FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
    * LAVA THERAPEUTICS NV - DATA FROM PHASE 1 DOSE ESCALATION
PHASE
OF STUDY ARE EXPECTED IN FIRST HALF OF 2022
    * LAVA THERAPEUTICS NV - TOP LINE CLINICAL DATA FROM PHASE
2A
EXPANSION COHORTS EXPECTED IN SECOND HALF OF 2022

Source text for Eikon:  ID:nGNX12G9Ym 
Further company coverage:  LVTX.O